{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:59:07Z","timestamp":1791219547217,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K02521"],"award-info":[{"award-number":["JP24K02521"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K24407"],"award-info":[{"award-number":["JP23K24407"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ck0106569h0003"],"award-info":[{"award-number":["JP22ck0106569h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The gut microbiota plays an essential role in regulating host immunity, and its metabolites such as butyrate exert immunomodulatory effects by acting as histone deacetylase inhibitors. Oncolytic virotherapy has emerged as a promising approach for cancer treatment, and we have developed OBP-702, a telomerase-specific oncolytic adenovirus that expresses p53 and elicits strong systemic antitumor responses. In this study, the potential synergy between butyrate and OBP-702 was investigated in colorectal cancer models. Using human and murine colorectal carcinoma cell lines, butyrate was found to directly enhance the infectivity of OBP-702 by upregulating CAR and integrins, thereby promoting apoptosis and autophagy in tumor cells. In addition, butyrate indirectly boosted systemic antitumor immunity by upregulating MHC-I expression through activation of the cGAS-STING pathway and enhancing CD8\u2009+\u2009T cell recruitment via CXCL10 secretion. These findings were supported by in vivo experiments using CT26 subcutaneous, bilateral, and orthotopic tumor models, in which the combination of oral butyrate and intratumoral OBP-702 administration produced synergistic antitumor effects. These results highlight the therapeutic potential of integrating gut microbial metabolites with oncolytic virotherapy as a novel immunotherapeutic strategy for colorectal cancer.<\/jats:p>","DOI":"10.1007\/s00262-025-04252-4","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:51:46Z","timestamp":1766062306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I\/cGAS-STING"],"prefix":"10.1007","volume":"75","author":[{"given":"Masaki","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4484-1253","authenticated-orcid":false,"given":"Shinji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mikane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Hanzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoma","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunitoshi","family":"Shigeyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Urata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"4252_CR1","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nrc3610","volume":"13","author":"RF Schwabe","year":"2013","unstructured":"Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13:800\u2013812. https:\/\/doi.org\/10.1038\/nrc3610","journal-title":"Nat Rev Cancer"},{"key":"4252_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/nm.4185","volume":"22","author":"BO Schroeder","year":"2016","unstructured":"Schroeder BO, Backhed F (2016) Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 22:1079\u20131089. https:\/\/doi.org\/10.1038\/nm.4185","journal-title":"Nat Med"},{"key":"4252_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4252_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-019-0406-6","volume":"25","author":"J Wirbel","year":"2019","unstructured":"Wirbel J, Pyl PT, Kartal E et al (2019) Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med 25:679\u2013689. https:\/\/doi.org\/10.1038\/s41591-019-0406-6","journal-title":"Nat Med"},{"key":"4252_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-019-0458-7","volume":"25","author":"S Yachida","year":"2019","unstructured":"Yachida S, Mizutani S, Shiroma H et al (2019) Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med 25:968\u2013976. https:\/\/doi.org\/10.1038\/s41591-019-0458-7","journal-title":"Nat Med"},{"key":"4252_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/1462-2920.13589","volume":"19","author":"P Louis","year":"2017","unstructured":"Louis P, Flint HJ (2017) Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol 19:29\u201341. https:\/\/doi.org\/10.1111\/1462-2920.13589","journal-title":"Environ Microbiol"},{"key":"4252_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/apt.17049","volume":"56","author":"EL Gulliver","year":"2022","unstructured":"Gulliver EL, Young RB, Chonwerawong M et al (2022) Review article: the future of microbiome-based therapeutics. Aliment Pharmacol Ther 56:192\u2013208. https:\/\/doi.org\/10.1111\/apt.17049","journal-title":"Aliment Pharmacol Ther"},{"key":"4252_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00262-008-0645-8","volume":"58","author":"C Zhang","year":"2009","unstructured":"Zhang C, Wang Y, Zhou Z, Zhang J, Tian Z (2009) Sodium butyrate upregulates expression of NKG2D ligand MICA\/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58:1275\u20131285. https:\/\/doi.org\/10.1007\/s00262-008-0645-8","journal-title":"Cancer Immunol Immunother"},{"key":"4252_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136741","author":"E Shklovskaya","year":"2021","unstructured":"Shklovskaya E, Rizos H (2021) MHC class I deficiency in solid tumors and therapeutic strategies to overcome it. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22136741","journal-title":"Int J Mol Sci"},{"key":"4252_CR10","doi-asserted-by":"publisher","first-page":"110880","DOI":"10.1016\/j.celrep.2022.110880","volume":"39","author":"X Wei","year":"2022","unstructured":"Wei X, Zhang L, Yang Y et al (2022) LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity. Cell Rep 39:110880. https:\/\/doi.org\/10.1016\/j.celrep.2022.110880","journal-title":"Cell Rep"},{"key":"4252_CR11","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1038\/s41467-020-17140-5","volume":"11","author":"A Finck","year":"2020","unstructured":"Finck A, Gill SI, June CH (2020) Cancer immunotherapy comes of age and looks for maturity. Nat Commun 11:3325. https:\/\/doi.org\/10.1038\/s41467-020-17140-5","journal-title":"Nat Commun"},{"key":"4252_CR12","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780\u20132788. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377","journal-title":"J Clin Oncol"},{"key":"4252_CR13","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M (2022) Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28:1630\u20131639. https:\/\/doi.org\/10.1038\/s41591-022-01897-x","journal-title":"Nat Med"},{"key":"4252_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1078-0432.ccr-1075-3","volume":"10","author":"T Kawashima","year":"2004","unstructured":"Kawashima T, Kagawa S, Kobayashi N et al (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10:285\u2013292. https:\/\/doi.org\/10.1158\/1078-0432.ccr-1075-3","journal-title":"Clin Cancer Res"},{"key":"4252_CR15","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-10-2333","volume":"70","author":"S Kuroda","year":"2010","unstructured":"Kuroda S, Fujiwara T, Shirakawa Y et al (2010) Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 70:9339\u20139348. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2333","journal-title":"Cancer Res"},{"key":"4252_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","volume":"153","author":"Y Shirakawa","year":"2021","unstructured":"Shirakawa Y, Tazawa H, Tanabe S et al (2021) Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments. Eur J Cancer 153:98\u2013108. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.043","journal-title":"Eur J Cancer"},{"key":"4252_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/mt.2009.262","volume":"18","author":"J Nemunaitis","year":"2010","unstructured":"Nemunaitis J, Tong AW, Nemunaitis M et al (2010) A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 18:429\u2013434. https:\/\/doi.org\/10.1038\/mt.2009.262","journal-title":"Mol Ther"},{"key":"4252_CR18","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ejca.2011.12.020","volume":"48","author":"Y Yamasaki","year":"2012","unstructured":"Yamasaki Y, Tazawa H, Hashimoto Y et al (2012) A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer 48:2282\u20132291. https:\/\/doi.org\/10.1016\/j.ejca.2011.12.020","journal-title":"Eur J Cancer"},{"key":"4252_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omto.2020.03.016","volume":"17","author":"T Koujima","year":"2020","unstructured":"Koujima T, Tazawa H, Ieda T et al (2020) Oncolytic virus-mediated targeting of the ERK signaling pathway inhibits invasive propensity in human pancreatic cancer. Mol Ther Oncolytics 17:107\u2013117. https:\/\/doi.org\/10.1016\/j.omto.2020.03.016","journal-title":"Mol Ther Oncolytics"},{"key":"4252_CR20","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","volume":"28","author":"N Kanaya","year":"2020","unstructured":"Kanaya N, Kuroda S, Kakiuchi Y et al (2020) Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody. Mol Ther 28:794\u2013804. https:\/\/doi.org\/10.1016\/j.ymthe.2020.01.003","journal-title":"Mol Ther"},{"key":"4252_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.omto.2022.04.009","volume":"25","author":"T Ogawa","year":"2022","unstructured":"Ogawa T, Kikuchi S, Tabuchi M et al (2022) Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer. Mol Ther Oncolytics 25:249\u2013261. https:\/\/doi.org\/10.1016\/j.omto.2022.04.009","journal-title":"Mol Ther Oncolytics"},{"key":"4252_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-022-03334-x","volume":"72","author":"Y Kajiwara","year":"2023","unstructured":"Kajiwara Y, Tazawa H, Yamada M et al (2023) Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunol Immunother 72:1285\u20131300. https:\/\/doi.org\/10.1007\/s00262-022-03334-x","journal-title":"Cancer Immunol Immunother"},{"key":"4252_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41416-024-02583-0","volume":"130","author":"M Hashimoto","year":"2024","unstructured":"Hashimoto M, Kuroda S, Kanaya N et al (2024) Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus. Br J Cancer 130:1187\u20131195. https:\/\/doi.org\/10.1038\/s41416-024-02583-0","journal-title":"Br J Cancer"},{"key":"4252_CR24","doi-asserted-by":"publisher","first-page":"1577906","DOI":"10.3389\/fmed.2025.1577906","volume":"12","author":"DA Gaskarth","year":"2025","unstructured":"Gaskarth DA, Fan S, Highton AJ, Kemp RA (2025) The microbial metabolite butyrate enhances the effector and memory functions of murine CD8+ T cells and improves anti-tumor activity. Front Med (Lausanne) 12:1577906. https:\/\/doi.org\/10.3389\/fmed.2025.1577906","journal-title":"Front Med (Lausanne)"},{"key":"4252_CR25","doi-asserted-by":"publisher","first-page":"14516","DOI":"10.1038\/s41598-017-15099-w","volume":"7","author":"C Nastasi","year":"2017","unstructured":"Nastasi C, Fredholm S, Willerslev-Olsen A, Hansen M, Bonefeld CM, Geisler C, Andersen MH, Odum N, Woetmann A (2017) Butyrate and propionate inhibit antigen-specific CD8(+) T cell activation by suppressing IL-12 production by antigen-presenting cells. Sci Rep 7:14516. https:\/\/doi.org\/10.1038\/s41598-017-15099-w","journal-title":"Sci Rep"},{"key":"4252_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.yexcr.2005.10.026","volume":"312","author":"T Watanabe","year":"2006","unstructured":"Watanabe T, Hioki M, Fujiwara T et al (2006) Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 312:256\u2013265. https:\/\/doi.org\/10.1016\/j.yexcr.2005.10.026","journal-title":"Exp Cell Res"},{"key":"4252_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3109\/07357900902783195","volume":"28","author":"K Kuster","year":"2010","unstructured":"Kuster K, Grotzinger C, Koschel A, Fischer A, Wiedenmann B, Anders M (2010) Sodium butyrate increases expression of the coxsackie and adenovirus receptor in colon cancer cells. Cancer Invest 28:268\u2013274. https:\/\/doi.org\/10.3109\/07357900902783195","journal-title":"Cancer Invest"},{"key":"4252_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27030862","author":"L Paparo","year":"2022","unstructured":"Paparo L, Maglio MA, Cortese M et al (2022) A new butyrate releaser exerts a protective action against SARS-CoV-2 infection in human intestine. Molecules. https:\/\/doi.org\/10.3390\/molecules27030862","journal-title":"Molecules"},{"key":"4252_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00326-20","author":"M Chemudupati","year":"2020","unstructured":"Chemudupati M, Kenney AD, Smith AC et al (2020) Butyrate reprograms expression of specific interferon-stimulated genes. J Virol. https:\/\/doi.org\/10.1128\/JVI.00326-20","journal-title":"J Virol"},{"key":"4252_CR30","doi-asserted-by":"publisher","first-page":"18437","DOI":"10.1073\/pnas.0508964102","volume":"102","author":"I Horikawa","year":"2005","unstructured":"Horikawa I, Chiang YJ, Patterson T, Feigenbaum L, Leem SH, Michishita E, Larionov V, Hodes RJ, Barrett JC (2005) Differential cis-regulation of human versus mouse TERT gene expression in vivo: identification of a human-specific repressive element. Proc Natl Acad Sci U S A 102:18437\u201318442. https:\/\/doi.org\/10.1073\/pnas.0508964102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4252_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020478","author":"H Tazawa","year":"2020","unstructured":"Tazawa H, Hasei J, Yano S, Kagawa S, Ozaki T, Fujiwara T (2020) Bone and soft-tissue sarcoma: a new target for telomerase-specific oncolytic virotherapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12020478","journal-title":"Cancers (Basel)"},{"key":"4252_CR32","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-20-0051","volume":"8","author":"Y Tomita","year":"2020","unstructured":"Tomita Y, Ikeda T, Sakata S et al (2020) Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol Res 8:1236\u20131242. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0051","journal-title":"Cancer Immunol Res"},{"key":"4252_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/nu17172734","author":"BA Napier","year":"2025","unstructured":"Napier BA, Allegretti JR, Feuerstadt P, Kelly CR, Van Hise NW, Jager R, Kassam Z, Reid G (2025) Multi-species synbiotic supplementation enhances gut microbial diversity, increases urolithin A and butyrate production, and reduces inflammation in healthy adults: a randomized, placebo-controlled trial. Nutrients. https:\/\/doi.org\/10.3390\/nu17172734","journal-title":"Nutrients"},{"key":"4252_CR34","doi-asserted-by":"publisher","first-page":"1603490","DOI":"10.3389\/fnut.2025.1603490","volume":"12","author":"N Hamari","year":"2025","unstructured":"Hamari N, Blaak EE, Canfora EE (2025) The impact of butyrate on glycemic control in animals and humans: a comprehensive semi-systemic review. Front Nutr 12:1603490. https:\/\/doi.org\/10.3389\/fnut.2025.1603490","journal-title":"Front Nutr"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04252-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:51:47Z","timestamp":1766062307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04252-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4252"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04252-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.U. is the President and CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-702. H.T. and T.F. are consultants of Oncolys BioPharma, Inc. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"10"}}